Healthcare Technology Firm Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With GE Healthcare

According to a registration statement with the SEC, Sophia Genetics SA SOPH is looking to raise $100 million in an initial public offering.
The firm has not disclosed the number of shares it will offer or the IPO price range.
With twin headquarters in Saint-Sulpice, Switzerland, and Boston, the bioinformatics company will trade on the NASDAQ under the ticker symbol SOPH.
J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse are serving as joint book-running managers for the offering.
To date, Sophia has raised at least $251 million in private equity, most recently in a $110 million Series F round that closed in October 2020.
The company offers a core genomic analytics platform called Data-Driven Medicine, a cloud-based SaaS platform to analyze data and generate insights from multimodal data sets and different diagnostic modalities.
The platform and related solutions are currently used by more than 750 hospitals, laboratories, and biopharma institutions globally.
Sophia also announced that it signed a letter of intent with GE Healthcare to co-develop new artificial intelligence-driven analytics and workflow technologies to improve the matching of treatments based on genetic and tumor profiles of cancer patients.